Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
GTx acquires exclusive rights in the U.S. for toremifene
January 13th, 2005
GTx, Inc., (GTXI), a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious men's health conditions, announced that it has signed an agreement with Orion Corp. (OMX) to purchase all remaining rights to toremifene in the U.S. and additional rights in all other countries. Toremifene is the active component in Acapodene (toremifene citrate), a product candidate that GTx is developing in late-stage clinical trials for two separate indications in men's health. The acquisition, which was expected to close by year-end, will make GTx the sole licensee of toremifene in the United States. Toremifene...
Source: Women's Health Weekly (2005-01-13)
|
